Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Mar 2023
FDA accepts for priority review ADX-2191 new drug application for the treatment of primary vitreoretinal lymphoma
2 March 2023 - PDUFA date is 21 June 2023. ...
Posted by Michael Wonder on 02 Mar 2023
Santhera submits marketing authorisation application to the UK MHRA for vamorolone in Duchenne muscular dystrophy
1 March 2023 - Santhera Pharmaceuticals announces that it has submitted a marketing authorisation application to the UK MHRA for ...
Posted by Michael Wonder on 02 Mar 2023
Boomerang Medical earns FDA breakthrough device designation
1 March 2023 - Boomerang Medical is currently enrolling a clinical trial studying a bioelectronic device for people living with Crohn’s ...
Posted by Michael Wonder on 02 Mar 2023
Affordable treatment for recurrent melanoma
2 March 2023 - From 1 March 2023, Australians with recurrent melanoma will have a new treatment option subsidised by the ...
Posted by Michael Wonder on 02 Mar 2023
PHARMAC confirms widened access for the funded flu vaccine
2 March 2023 - PHARMAC is widening access to the annual funded flu vaccine to tamariki aged 6 months to 12 ...
Posted by Michael Wonder on 01 Mar 2023
Pfizer and BioNTech submit for US emergency use authorisation of Omicron BA.4/BA.5 adapted bivalent COVID-19 booster in children under 5 years
1 March 2023 - Pfizer and BioNTech today submitted an application to the US FDA for emergency use authorisation of ...
Posted by Michael Wonder on 01 Mar 2023
A review of patient reported outcome considerations in Oncologic Drugs Advisory Committee meetings (2016-2021)
28 February 2023 - The purpose of this project was to gain insight into the role of patient reported outcome data ...
Posted by Michael Wonder on 01 Mar 2023
ABPI sets out new proposals to support the NHS and economic growth
1 March 2023 - The pharmaceutical industry’s offer includes an annual £1 billion boost to the NHS as well as an ...
Posted by Michael Wonder on 01 Mar 2023
Obesity drugs often aren't covered by insurance. Experts say this limits access, increases disparities.
28 February 2023 - Over 40% of Americans have obesity, the CDC says. ...
Posted by Michael Wonder on 01 Mar 2023
ICER publishes evidence report on lecanemab for Alzheimer’s disease
1 March 2023 - Currently available evidence is rated as promising but inconclusive to determine whether lecanemab provides a net health ...
Posted by Michael Wonder on 01 Mar 2023
Nexus Pharmaceuticals receives FDA approval for Emerphed (ephedrine sulphate injection) pre-filled syringe
1 March 2023 - Nexus Pharmaceuticals announced that it has received US FDA approval for Emerphed (ephedrine sulphate injection) in 25 ...
Posted by Michael Wonder on 01 Mar 2023
The drug prices review board was once a solution. It’s now a problem.
1 March 2023 - Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada. ...
Posted by Michael Wonder on 01 Mar 2023
Lilly cuts insulin prices by 70% and caps patient insulin out of pocket costs at $35 per month
1 March 2023 - Eli Lilly today announced price reductions of 70% for its most commonly prescribed insulins and an expansion ...
Posted by Michael Wonder on 01 Mar 2023
Janssen submits new drug application to the US FDA seeking approval of niraparib and abiraterone acetate dual action tablet, plus prednisone, as a first-line targeted treatment for patients with metastatic castration-resistant prostate cancer with BRCA gene mutations
28 February 2023 - Niraparib and abiraterone acetate plus prednisone has potential to address unmet need for patients with BRCA ...
Posted by Michael Wonder on 01 Mar 2023
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE
1 March 2023 - Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by ...